Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.16 AUD
Change Today 0.00 / 0.00%
Volume 0.0
PGL On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 8:06 PM 08/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2806 Ipswich Road

Darra, QLD 4076

Australia

Phone: 61 7 3273 9133

Fax: 61 7 3375 1168

Progen Pharmaceuticals Limited, a biotechnology company, engages in the discovery, development, and commercialization of small molecule therapeutics primarily for the treatment of cancer. Products PI-88 PI-88 is a carbohydrate-based small-molecule, which is believed to work through two mechanisms. Firstly, it inhibits the enzyme heparanase, which plays a primary role in tumor spread and invasion through surrounding tissues. Secondly, PI-88 exerts an anti-angiogenic effect by inhibiting the interaction between growth factors, heparan sulfate, and cellular receptors. The company has a license and collaboration agreement has been executed with Medigen Biotechnology Corporation (Medigen) for the development and commercialization of muparfostat worldwide. The agreement grants Medigen worldwide and sub-license rights for the commercialization of muparfostat for the therapeutic and prophylactic treatment of cancer. The company has an exclusive worldwide license from the Australian National University in Canberra, Australia, to five families of patents and patent applications relating to PI-88, its sulfated oligosaccharide heparanase inhibitor. Its license rights terminate in 2026. PG545 PG545 is a proprietary synthetic small molecule created to modulate the tumour microenvironment through multiple mechanisms of action. In 2014, the company completed treatment of the first patient cohort where each patient in this group received once-weekly 25mg doses of PG545. PharmaSynth Pty Ltd (PharmaSynth) PharmaSynth, a subsidiary of the company, provides contract pharmaceutical manufacturing development services to the biotechnology industry; and manufactures material for phase 1 to phase 3 clinical trials, as well as manufactures veterinary and animal health products. Trademarks Progen is a registered trademark of the company. History The company was founded in 1989. It was incorporated in 1989 as Almagest Pty. Ltd. in the state of Queensland, Australia. The company changed its name to Progen Industries Pty. Ltd. in 1990 and then to Progen Industries Limited in 1991. Further, the company changed its name to Progen Pharmaceuticals Limited in 2007.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGL:AU A$0.16 AUD 0.00

PGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PGL.
View Industry Companies
 

Industry Analysis

PGL

Industry Average

Valuation PGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGEN PHARMACEUTICALS LTD, please visit www.progen-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.